Protocatechuic aldehyde ameliorates experimental pulmonary fibrosis by modulating HMGB1/RAGE pathway

Toxicology and Applied Pharmacology

Volumn 283, Issue 1, 2015, Pages 50-56

  Zhang, Liang ^a   Ji, Yunxia ^a   Kang, Zechun ^a   Lv, Changjun ^a   Jiang, Wanglin ^a  

^a BINZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Epithelial mesenchymal transition; Fibroblast growth factor 2; High mobility group box 1; Protocatechuic aldehyde; Pulmonary fibrosis; Receptor for advanced glycation end product

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; ALPHA SMOOTH MUSCLE ACTIN; BLEOMYCIN; COLLAGEN; FIBROBLAST GROWTH FACTOR 2; HIGH MOBILITY GROUP B1 PROTEIN; PLATELET DERIVED GROWTH FACTOR; PROTOCATECHUALDEHYDE; TRANSFORMING GROWTH FACTOR BETA1; VIMENTIN; ACTIN; ADVANCED GLYCOSYLATION END-PRODUCT RECEPTOR; BENZALDEHYDE DERIVATIVE; CATECHOL DERIVATIVE; HBP1 PROTEIN, RAT; HMGB1 PROTEIN, HUMAN; IMMUNOGLOBULIN RECEPTOR; SMALL INTERFERING RNA; SMOOTH MUSCLE ACTIN, RAT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; LUNG ALVEOLUS EPITHELIUM CELL; LUNG FIBROBLAST; LUNG FIBROSIS; MALE; NONHUMAN; PROTEIN EXPRESSION; RAT; ANIMAL; CELL LINE; CHEMICALLY INDUCED; DRUG EFFECTS; GENETICS; LUNG; METABOLISM; PATHOLOGY; PULMONARY FIBROSIS; SIGNAL TRANSDUCTION; SPRAGUE DAWLEY RAT; TUMOR CELL LINE;

RATTUS;

ACTINS; ANIMALS; APOPTOSIS; BENZALDEHYDES; BLEOMYCIN; CATECHOLS; CELL LINE; CELL LINE, TUMOR; CELL PROLIFERATION; COLLAGEN; EPITHELIAL-MESENCHYMAL TRANSITION; FIBROBLAST GROWTH FACTOR 2; HMGB1 PROTEIN; HUMANS; LUNG; MALE; PLATELET-DERIVED GROWTH FACTOR; PULMONARY FIBROSIS; RATS, SPRAGUE-DAWLEY; RECEPTORS, IMMUNOLOGIC; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84921299153     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2015.01.001     Document Type: Article

References (27)

1. Abe S., Hayashi H., Seo Y., et al. Reduction in serum high mobility group box-1 level by polymyxin B-immobilized fiber column in patients with idiopathic pulmonary fibrosis with acute exacerbation. Blood Purif. 2011, 32(4):310-316.
2. Ashcroft T., Simpson J.M., Timbrell V. Simple method of estimating severity of pulmonary fibrosis on a numerical scale. J. Clin. Pathol. 1988, 41(4):467-470.
3. Bocchino M., Agnese S., Fagone E. Reactive oxygen species are required for maintenance and differentiation of primary lung fibroblasts in idiopathic pulmonary fibrosis. PLoS ONE 2010, 5(11):e14003.
4. Chaudhary N.I., Roth G.J., Hilberg F., et al. Inhibition of PDGF, VEGF and FGF signalling attenuates fibrosis. Eur. Respir. J. 2007, 29(5):976-985.
5. Datta A., Scotton C.J., Chambers R.C. Novel therapeutic approaches for pulmonary fibrosis. Br. J. Pharmacol. 2011, 163(1):141-172.
6. Ebina M., Taniguchi H., Miyasho T., et al. Gradual increase of high mobility group protein b1 in the lungs after the onset of acute exacerbation of idiopathic pulmonary fibrosis. Pulm. Med. 2011, 2011:916486.
7. Englert J.M., Hanford L.E., Kaminski N., et al. A role for the receptor for advanced glycation end products in idiopathic pulmonary fibrosis. Am. J. Pathol. 2008, 172(3):583-591.
8. Ge W.S., Wu J.X., Fan J.G. Inhibition of high-mobility group box 1 expression by siRNA in rat hepatic stellate cells. World J. Gastroenterol. 2011, 17(36):4090-4098.
9. Hamada N., Maeyama T., Kawaguchi T., et al. The role of high mobility group box 1 in pulmonary fibrosis. Am. J. Respir. Cell Mol. Biol. 2008, 39(4):440-447.
10. Hori O., Brett J., Slattery T., et al. The receptor for advanced glycation end products (RAGE) is a cellular binding site for amphoterin. Mediation of neurite outgrowth and co-expression of rage and amphoterin in the developing nervous system. J. Biol. Chem. 1995, 270(43):25752-25761.
11. Katzenstein A.L., Myers J.L. Idiopathic pulmonary fibrosis: clinical relevance of pathologic classification. Am. J. Respir. Crit. Care Med. 1998, 157(4 Pt 1):1301-1315.
12. Kim K.J., Kim M.A., Jung J.H. Antitumor and antioxidant activity of protocatechualdehyde produced from Streptomyces lincolnensis M-20. Arch. Pharm. Res. 2008, 31(12):1572-1577.
13. King T.E., Pardo A., Selman M. Idiopathic pulmonary fibrosis. Lancet 2011, 378(9807):1949-1961.
14. Loughlin P.M., Cooke T.G., George W.D. Quantifying tumour-infiltrating lymphocyte subsets: a practical immuno-histochemical method. J. Immunol. Methods 2007, 321(102):32-40.
15. Queisser M.A., Kouri F.M., Königshoff M., et al. Loss of RAGE in pulmonary fibrosis: molecular relations to functional changes in pulmonary cell types. Am. J. Respir. Cell Mol. Biol. 2008, 39(3):337-345.
16. Raghu G., Collard H.R., Egan J. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am. J. Respir. Crit. Care Med. 2011, 183(6):788-824.
17. Scaffidi P., Misteli T., Bianchi M.E. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 2002, 418(6894):191-195.
18. Selman M., Pardo A. Role of epithelial cells in idiopathic pulmonary fibrosis: from innocent targets to serial killers. Proc. Am. Thorac. Soc. 2006, 3(4):364-372.
19. Selman M., King T.E., Pardo A. Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann. Intern. Med. 2001, 134(2):136-151.
20. Shi M.Q., Su F.F., Li W.J. Effects of HMGB1 on proliferation, collagen type I, III mRNA expression in cardiac fibroblasts. Sci. Technol. Eng. 2010, 10:7402-7406.
21. Shi Y., Gochuico B.R., Yu G., et al. Syndecan-2 exerts antifibrotic effects by promoting caveolin-1-mediated transforming growth factor-β receptor I internalization and inhibiting transforming growth factor-β1 signaling. Am. J. Respir. Crit. Care Med. 2013, 188(7):831-841.
22. Tanaka K., Ishihara T., Azuma A., et al. Therapeutic effect of lecithinized superoxide dismutase on bleomycin-induced pulmonary fibrosis. Am. J. Physiol. Lung Cell. Mol. Physiol. 2010, 298(3):L348-L360.
23. Thannickal V.J., Horowitz J.C. Evolving concepts of apoptosis in idiopathic pulmonary fibrosis. Proc. Am. Thorac. Soc. 2006, 3(4):350-356.
24. Ueno H., Matsuda T., Hashimoto S., et al. Contributions of high mobility group box protein in experimental and clinical acute lung injury. Am. J. Respir. Crit. Care Med. 2004, 170(12):1310-1316.
25. Wang H.D., Yamaya M., Okinaga S., et al. Bilirubin ameliorates bleomycin-induced pulmonary fibrosis in rats. Am. J. Respir. Crit. Care Med. 2002, 165(3):406-411.
26. Xu Y., Jiang W.L., Zhang S.P., et al. Protocatechuic aldehyde protects against experimental sepsis in vitro and in vivo. Basic Clin. Pharmacol. Toxicol. 2012, 110(4):384-389.
27. Zhou Z., Liu Y., Miao A.D. Protocatechuic aldehyde suppresses TNF-alpha-induced ICAM-1 and VCAM-1 expression in human umbilical vein endothelial cells. Eur. J. Pharmacol. 2005, 513(1-2):1-8.